Developments in T Cell Based Cancer Immunotherapies de Paolo A. Ascierto

Developments in T Cell Based Cancer Immunotherapies: Cancer Drug Discovery and Development

Editat de Paolo A. Ascierto, David F. Stroncek, Ena Wang

en Limba Engleză Paperback – 14 mar 2019

This volume illustrates the salient aspects of cancer biology relevant to the successful implementation of immunotherapy. Topics include enhancement of antigen-specific immune responses by anti-cancer vaccines, modulation of the function of T cells within the tumor microenvironment, and the effects of genetic, epigenetic, developmental, and environmental determinants on T cell function. Other topics covered include the ex vivo expansion of T or other immune cells and their genetic modification or reprogramming to increase their ability to survive and expand when adoptively transferred back to the patients. Specific attention is devoted to the genetic manipulation of T cells through the introduction of re-directed T cell receptors, chimeric antibody receptors, and other genetic manipulation aimed at improving their effectiveness as anti-cancer agents. Furthermore, the revolutionary role of checkpoint inhibitors and their potential in combination with other immunotherapeutic approaches or with standard chemo and radiation therapy are extensively discussed.

Citește tot Restrânge

Toate formatele și edițiile

	Preț	Express
Paperback (1)	1061^.96 lei 39-44 zile
Springer International Publishing – 14 mar 2019	1061^.96 lei 39-44 zile
Hardback (1)	1065^.32 lei 3-5 săpt.
Springer International Publishing – 4 dec 2015	1065^.32 lei 3-5 săpt.

Din seria Cancer Drug Discovery and Development

Preț: 1061^.96 lei

Preț vechi: 1117^.85 lei
-5%

Puncte Express: 1593

:
187^.74€ • 223^.16$ • 162^.90£

Carte tipărită la comandă

Livrare economică 09-14 martie

Adaugă în coș

Wish list
Gift list
Am citit!

Adaugă în listă

Specificații

ISBN-13: 9783319793306
ISBN-10: 3319793306
Pagini: 305
Ilustrații: XV, 305 p. 26 illus. in color.
Dimensiuni: 155 x 235 mm
Ediția:Softcover reprint of the original 1st ed. 2015
Editura: Springer International Publishing
Colecția Humana
Seria Cancer Drug Discovery and Development

Locul publicării:Cham, Switzerland

Cuprins

1 New insight of peptidevaccination in cancer immunotherapy.- 2 The determinants of T cell function foreffective anticancer vaccine.- 3 T cell fate in the tumor microenvironment.- 4T cell receptor avidity and affinity and tumor specific TCR engineer .- 5 Hostgenetic variation and somatic alteration associated with favorable orcompromised T cell function.- 6 Production of Clinical T Cell Therapies.- 7Clinical success of adoptive cell transfer therapy using tumor infiltratinglymphocytes.-8 Harnessing stem cell-like memory T cells for adoptive celltransfer therapy of cancer .- 9 T cell blockade- anti-CTLA4 immunotherapyagainst cancer and Abscopal effect in combination therapy.- 10 T cellmodulation- anti-OD-1 antibodies for the treatment of cancer.- 11 T cell basedtherapies in combination with other procedures.- 12 Chimeric antigen receptor Tcells CD19 CAR.- 13 Hematopoietic Stem Cell transplantation as immune therapyof malignancies.

Notă biografică

Ena Wang, MD, is Director of Molecular Science, Infectious Diseases and Immunogenetics Section at the National Institutes of Health. The focus of her research is the identification of genetic traits in humans that could explain the relationship between pathogens and the host with particular interest in cancer and chronic infections During her career at NIH, Dr. Wang was twice granted the Investigator Travel Fellowship Award; received an NIH Bench-to-Bedside Award in 2002; received the Minority Award as a mentor and principle investigator in 2002; received the NCI Director’s 2006 Intramural Innovation Award as co-investigator in 2006; and received the Clinic Center Director’s Award for scientific excellence in 2007. Dr. Wang has authored 17 book chapters and published more than 130 peer reviewed articles. Her scientific papers have received more than 6,500 citations.
Paolo Antonio Ascierto, MD, is Vice Director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Institute Fondazione G. Pascale in Naples, Italy. Dr. Ascierto has published more than 117 scientific papers, which have received more than 2,100 citations.
David F. Stroncek, MD, is the Chief of the Cell Processing Section at the Department of Transfusion Medicine at the National Institutes of Health. Dr. Stroncek has published more than 264 scientific papers, which have received more than 5,300 citations.

Textul de pe ultima copertă

This volume illustrates the salient aspects of cancer biology relevant to the successful implementation of immunotherapy. Topics include enhancement of antigen-specific immune responses by anti-cancer vaccines, modulation of the function of T cells within the tumor microenvironment, and the effects of genetic, epigenetic, developmental, and environmental determinants on T cell function. Other topics covered include the ex vivo expansion of T or other immune cells and their genetic modification or reprogramming to increase their ability to survive and expand when adoptively transferred back to the patients. Specific attention is devoted to the genetic manipulation of T cells through the introduction of re-directed T cell receptors, chimeric antibody receptors, and other genetic manipulation aimed at improving their effectiveness as anti-cancer agents. Furthermore, the revolutionary role of checkpoint inhibitors and their potential in combination with other immunotherapeutic approaches or with standard chemo and radiation therapy are extensively discussed.

Caracteristici

Summarizes and discusses current advancements in T cell-based anticancer immunotherapy Comprehensively covers T cell biology, including T cell lineage differentiation stages, mechanisms of anergy and activation, exhaustion, senescence, stemness, and strategies of deregulation for therapeutic development Explores novel approach of hematopoietic stem cell transplantation as a method of immune therapy for cancer

Descriere

Descriere de la o altă ediție sau format:

This volume illustrates the salient aspects of cancer biology relevant to the successful implementation of immunotherapy. Topics include enhancement of antigen-specific immune responses by anti-cancer vaccines, modulation of the function of T cells within the tumor microenvironment, and the effects of genetic, epigenetic, developmental, and environmental determinants on T cell function. Other topics covered include the ex vivo expansion of T or other immune cells and their genetic modification or reprogramming to increase their ability to survive and expand when adoptively transferred back to the patients. Specific attention is devoted to the genetic manipulation of T cells through the introduction of re-directed T cell receptors, chimeric antibody receptors, and other genetic manipulation aimed at improving their effectiveness as anti-cancer agents. Furthermore, the revolutionary role of checkpoint inhibitors and their potential in combination with other immunotherapeutic approaches or with standard chemo and radiation therapy are extensively discussed.